High Serum PD-L1 Levels Are Associated with Poor Survival in Urothelial Cancer Patients Treated with Chemotherapy and Immune Checkpoint Inhibitor Therapy

Antibody-Drug Conjugates in Urothelial Carcinomas

(2020) Michal Sarfaty et al.   Current Oncology Reports

European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines

(2020) J. Alfred Witjes et al.   EUROPEAN UROLOGY

Expression of Nectin-4 and PD-L1 in Upper Tract Urothelial Carcinoma

(2020) Eisuke Tomiyama et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

MMP-7 Serum and Tissue Levels Are Associated with Poor Survival in Platinum-Treated Bladder Cancer Patients

(2020) Tibor Szarvas et al.   Diagnostics

Soluble Ligand of the Immune Checkpoint Receptor (sPD-L1) in Blood Serum of Patients with Renal Cell Carcinoma

(2019) N. E. Kushlinskii et al.   BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE

Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy

(2019) Tetsuro Tominaga et al.   PLoS One

Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial

(2019) Thomas Powles et al.   NATURE MEDICINE

A húgyhólyag urothelialis daganatainak molekuláris alcsoportbeosztása és annak klinikai vonatkozásai

(2019) Tibor Szarvas et al.   ORVOSI HETILAP

Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab

(2018) Adrien Costantini et al.   OncoImmunology

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression

(2018) Tsunehiko Shigemori et al.   ANNALS OF SURGICAL ONCOLOGY

FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin‐Containing Chemotherapy

(2018) Daniel L. Suzman et al.   ONCOLOGIST

Regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment is mediated through matrix metalloproteinase-mediated proteolytic cleavage

(2017) Mayuko Hira-Miyazawa et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

(2017) Arjun V Balar et al.   LANCET

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

(2017) Joaquim Bellmunt et al.   NEW ENGLAND JOURNAL OF MEDICINE

FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum‐Containing Chemotherapy

(2017) Yang‐Min Ning et al.   ONCOLOGIST

sPD-L1 Expression is Associated with Immunosuppression and Infectious Complications in Patients with Acute Pancreatitis

(2017) Y. Chen et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

PD-L1 expression in bladder cancer and metastasis and its influence on oncologic outcome after cystectomy

(2017) Renate Pichler et al.   Oncotarget

Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer

(2017) Xinxin Zhu et al.   Oncotarget

ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy

(2016) Floris H. Groenendijk et al.   EUROPEAN UROLOGY

PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma

(2016) Melanie Ruf et al.   INTERNATIONAL JOURNAL OF CANCER

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

(2016) Jonathan E Rosenberg et al.   LANCET

Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma

(2016) Takehiko Fukuda et al.   Cancer Medicine

A novel regulation of PD-1 ligands on mesenchymal stromal cells through MMP-mediated proteolytic cleavage

(2015) Colette Dezutter-Dambuyant et al.   OncoImmunology

High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial

(2014) D Rossille et al.   LEUKEMIA

Urinary matrix metalloproteinase-7 level is associated with the presence of metastasis in bladder cancer

(2010) Tibor Szarvas et al.   BJU INTERNATIONAL

Matrix metalloproteinase-7 as a marker of metastasis and predictor of poor survival in bladder cancer

(2010) Tibor Szarvas et al.   CANCER SCIENCE